Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Allergan tried a new way to protect a lucrative drug. Photo: Jean-Pierre Clatot/AFP via Getty Images
A federal appeals court Friday delivered a blow to drug maker Allergan, saying in a ruling the Saint Regis Mohawk Tribe cannot assert its "tribal sovereign immunity" to cast aside patent challenges to one of Allergan's drugs. Allergan declined to comment.
Flashback: Last year, Allergan transferred the patents of its blockbuster dry eye drug, Restasis, to Saint Regis and agreed to pay the Native American tribe money. In return, the tribe would attempt to kill patent challenges from generic drug companies that wanted to make cheaper versions of the drug.